View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on NSCLC from the 2018 European Oncology Congress in Munich.
1.0 AMA PRA Category 1 Credit(s)™
Apr 15, 2019
Apr 15, 2020
Abstract #1469P: EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients
Featured Expert: Fabrice Barlesi, MD, PhD
Abstract #LBA54: IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
Featured Expert: Fabrice Barlesi, MD, PhD
Abstract #LBA62: Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407
Featured Expert: Luis Paz-Ares, MD
Abstract #LBA63: Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)
Featured Expert: Roy S. Herbst, MD, PhD
Abstract #LBA50: Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study
Featured Expert: Suresh Ramalingam, MD
Fabrice Barlesi, MD, PhDAssitance Publique
Hôpitaux De Marseille
Roy S. Herbst, MD, PhDYale Cancer Center
New Haven, Connecticut, United States
Luis Paz-Ares, MDHospital Universitario 12 de Octubre
Suresh Ramalingam, MDWinship Cancer Institute
Atlanta, Georgia, United States
This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.
After successful completion of this educational activity, participants should be able to:
- Identify clinical trial data presented at 2018 European Oncology Congress in Munich
- Incorporate new findings presented in Munich into patient treatment regimens, where applicable
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1 hour
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Barlesi has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda. He also disclosed independent contracting for AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, MedImmune, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda. He also disclosed speaking and teaching for AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Novartis, Merck, Merck Sharp & Dohme, Pierre Fabre, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Herbst has disclosed that he has received consulting fees from Abbvie Pharmaceuticals, AstraZeneca, Biodesix, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Heat Biologics, Jun Shi Pharmaceuticals, Loxo Oncology, Merck and Company, Nektar, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, and Tesaro. He received research support from AstraZeneca, Eli Lilly and Company, and Merck and Company. He has also served on scientific advisory boards for Infinity Pharmaceuticals, Neon Therapeutics, and NextCure. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Paz-Ares has disclosed that he has received honoraria from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer, Celgene, Incyte, Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Roche, Servier, and Sysmex. He also disclosed institutional financial interests from AstraZeneca, Bristol-Myers Squibb, and Merck Sharp & Dohme. He has disclosed that he is a board member of Genomica. He also disclosed that he is a scientific chair and member of the Board of Asociación Española Contra el Cáncer (AECC: Majoir Spanish Anti-Cancer Charity). Furthermore, his wife has been an EMA SAG member, which concluded in June 2017. She also has received honoraria from July 2017 onwards from Amgen, Ipsen, Merck, Novartis, Pfizer, Roche, Servier, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ramalingam has disclosed that he has performed contracted research for Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, and Tesaro. He has disclosed that he has received consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Loxo, Merck, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.